Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.

Name: Αlpha¹ Rigor Record — Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Item: Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Rating: 100
Author: Αlpha¹

Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, Colhoun HM, Cercato C, Dicker D, Horn DB, Hovingh GK, Jeppesen OK, Kokkinos A, Lincoff AM, Meyhöfer SM, Oral TK, Plutzky J, van Beek AP, Wilding JPH, Kushner RF

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.5★ (Strong), 0 critical, 0 high issues for “Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.5 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced1 type

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported prespecified secondary analysis of a large randomized controlled trial. The paper demonstrates strong methodological rigor across all eight dimensions, with only minor reporting gaps (e.g., randomization method not detailed, no explicit reporting guideline statement, assumptions not explicitly verified).

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal-related, cell line, code sharing). The statistics verification checked 4 tests, all consistent; the citation check found no retracted or unresolved references; the reproducibility check confirmed the data link is live.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 3 via agent-written checks.

Reporting

Eight Dimensions8 pass

The introduction cites prior work on obesity prevalence, the relationship between body fat and cardiovascular disease, and the development of weight-management medications including semaglutide. It acknowledges the challenge of sustaining weight loss with lifestyle intervention alone and references prior semaglutide trials (e.g., STEP 1). The rationale for this prespecified analysis is clearly stated: to evaluate weight loss and anthropometric outcomes in a diverse population over 208 weeks. Limitations of prior research are implicitly addressed by noting the need for long-term data in diverse populations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on obesity, weight loss, and semaglutide, and logically links it to the study objectives.

Evidence

paraphrase[Introduction, paragraph 3]

“In STEP 1, a large phase 3 study of once-weekly subcutaneous semaglutide 2.4 mg in individuals without diabetes but with BMI >30 kg m − 2 or 27 kg m − 2 with at least one obesity-related comorbidity, the mean weight loss was −14.9% at week 68, compared with −2.4% with placebo.”

direct quote[Introduction, last paragraph]

“This prespecified analysis of the SELECT trial investigated weight loss and changes in anthropometric indices in patients with established CVD and overweight or obesity without diabetes, who met inclusion and exclusion criteria, within a range of baseline categories for glycemia, renal function and body anthropometric measures.”